Diurnal Looking To Secure US Partner Soon For Alkindi

Following the successful launch of Alkindi in a number of European countries, the UK's Diurnal Group PLCis laying the groundwork for a US launch for the replacement therapy for adrenal insufficiency in infants.

The biotech, one of the very few in the UK to have taken a product from concept to commercialization on its own, has unveiled its plans for Alkindi (immediate-release hydrocortisone) across the Atlantic and reflected on its progress closer to home. Approved two years ago through the European Medicines Agency's pediatric-use marketing authorization (PUMA) pathway, Alkindi was initially launched in Germany, the UK and Austria and is now also available in Sweden, Denmark, Norway, Iceland and since last week Italy